Elicio Therapeutics

(NASDAQ) ELTX

Current Price$9.62

Market Cap$182.65M

Since IPO (2023)-41%

5 Year-94%

1 Year+80%

1 Month-29%

Elicio Therapeutics Financials at a Glance

Market Cap

$182.65M

Revenue (TTM)

$0.00

Net Income (TTM)

$40.19M

EPS (TTM)

$-2.34

P/E Ratio

-4.08

Dividend

$0.00

Beta (Volatility)

1.08 (Average)

Dividend

$0.00

Beta (Volatility)

1.08 (Average)

Price

$9.62

Volume

5,013

Open

$10.52

Price

$9.62

Volume

5,013

Open

$10.52

Previous Close

$9.62

Daily Range

$9.44 - $10.52

52-Week Range

$5.15 - $14.93

Dividend

$0.00

Beta (Volatility)

1.08 (Average)

Price

$9.62

Volume

5,013

Open

$10.52

Previous Close

$9.62

Daily Range

$9.44 - $10.52

52-Week Range

$5.15 - $14.93

ELTX News

Elicio (ELTX) Q2 Loss Beats Estimates

Motley Fool Markets TeamAug 7, 2025

ELTX: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Elicio Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Robert T. Connelly

Website

www.elicio.com

Headquarters

Boston, MA 02210, US

ELTX Financials

Key Financial Metrics (TTM)

Gross Margin

Operating Margin

Net Income Margin

Return on Equity

-1076%

Return on Capital

-2%

Return on Assets

-2%

Earnings Yield

-24.51%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$182.65M

Shares Outstanding

19.09M

Volume

5.01K

Avg. Volume

138.39K

Financials (TTM)

Gross Profit

$1.13M

Operating Income

$37.71M

EBITDA

$36.59M

Operating Cash Flow

$36.95M

Capital Expenditure

$16.00K

Free Cash Flow

$36.97M

Cash & ST Invst.

$18.56M

Total Debt

$14.51M

Elicio Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$289.00K

-4.0%

Gross Margin

0.00%

N/A

Market Cap

$182.65M

N/A

Market Cap/Employee

$5.71M

N/A

Employees

N/A

Net Income

$11.82M

-5.5%

EBITDA

$10.31M

+4.1%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Net Cash

$10.08M

-19.7%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$3.82M

-21.4%

Short Term Debt

$1.04M

+12.5%

Return on Assets

-1.77%

N/A

Return on Invested Capital

-2.43%

N/A

Free Cash Flow

$11.64M

-15.1%

Operating Cash Flow

$11.64M

-15.1%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

NKTXNkarta, Inc.

NKTXNkarta, Inc.$2.68+1.52%

MOLNMolecular Partners AG

MOLNMolecular Partners AG$3.80-0.09%

MISTMilestone Pharmaceuticals Inc.

MISTMilestone Pharmaceuticals Inc.$1.46-2.99%

CRBPCorbus Pharmaceuticals Holdings, Inc.

CRBPCorbus Pharmaceuticals Holdings, Inc.$9.95-9.79%

CRDFCardiff Oncology, Inc.

CRDFCardiff Oncology, Inc.$1.69+1.20%

PEPGPepGen Inc.

PEPGPepGen Inc.$1.47-5.16%

RANIRani Therapeutics Holdings, Inc.

RANIRani Therapeutics Holdings, Inc.$0.97-9.97%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NOKNokia

NOKNokia$13.74-0.02%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$14.20-0.06%

TET1 Energy Inc.

TET1 Energy Inc.$7.00+0.23%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$74.32-0.01%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$43.54+0.01%

ONDSOndas

ONDSOndas$9.70-0.09%

POETPoet Technologies

POETPoet Technologies$14.21-0.11%

Questions About ELTX

What is the current price of Elicio Therapeutics?

Elicio Therapeutics is trading at $9.62 per share.

What is the 52-week range for Elicio Therapeutics?

Over the past 52 weeks, Elicio Therapeutics has traded between $5.15 and $14.93.

How much debt does Elicio Therapeutics have?

As of the most recent reporting period, Elicio Therapeutics reported total debt of $14.34M.

How much cash does Elicio Therapeutics have on hand?

Elicio Therapeutics reported $14.95M in cash and cash equivalents in its most recent financial results.

What is Elicio Therapeutics’s dividend yield?

Elicio Therapeutics does not currently have a dividend yield.

Elicio Therapeutics

Elicio Therapeutics Financials at a Glance

ELTX News

Elicio (ELTX) Q2 Loss Beats Estimates

ELTX: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Elicio Therapeutics

ELTX Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Elicio Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About ELTX

What is the current price of Elicio Therapeutics?

What is the 52-week range for Elicio Therapeutics?

How much debt does Elicio Therapeutics have?

How much cash does Elicio Therapeutics have on hand?

What is Elicio Therapeutics’s dividend yield?

Premium Investing Services